Nuclear Medicine/Radiopharmaceuticals Market

Cardinal Health (US), Curium (France) and GE Healthcare (US) are Leading Players in the Nuclear Medicine/Radiopharmaceuticals Market

The nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8 billion in 2021, at a CAGR of 9.0% during the forecast period.  Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

Some of the prominent players operating in the nuclear medicine market include Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

To know about the assumptions considered for the study download the pdf brochure

Top Nuclear Medicine Market Major Players

Cardinal Health was the leading player in the nuclear medicine market in 2020. The company has a robust network of nuclear pharmacies and focuses on expanding its PET manufacturing capabilities. The company strongly believes in the diversification of its customer base by establishing independent pharmacies and other pharmacy channels.

Curium held the second-leading position in the nuclear medicine market in 2020. The company focuses on innovation improving its geographic presence through partnerships with different market players to maintain its position as a leading player globally.

GE Healthcare held the third-leading position in the nuclear medicine market in 2020. GE healthcare’s strong position in the global market can be attributed to its comprehensive product portfolio as well as its strong geographic presence The company robust portfolio for nuclear medicine market, a large number of subsidiaries and focus on customers have contributed to its leading position in the nuclear medicine market.

Related Reports:

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology,Cardiology), Procedures - Global Forecast to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
PH 3590
RI Published ON
9/2/2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine/Radiopharmaceuticals Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved